160 related articles for article (PubMed ID: 35852114)
1. Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report.
Anastasopoulou A; Gkoufa A; Diamantopoulos P; Kazanas S; Eliadi I; Samarkos M; Gogas H
Immunotherapy; 2022 Sep; 14(13):1015-1020. PubMed ID: 35852114
[TBL] [Abstract][Full Text] [Related]
2. PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Eggermont AM; Ascierto PA; Khushalani NI; Schadendorf D; Boland G; Weber J; Lewis KD; Johnson D; Rivalland G; Khattak A; Majem M; Gogas H; Long GV; Currie SL; Chien D; Tagliaferri MA; Carlino MS; Diab A
Future Oncol; 2022 Mar; 18(8):903-913. PubMed ID: 35073733
[TBL] [Abstract][Full Text] [Related]
3. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Diab A; Tykodi SS; Daniels GA; Maio M; Curti BD; Lewis KD; Jang S; Kalinka E; Puzanov I; Spira AI; Cho DC; Guan S; Puente E; Nguyen T; Hoch U; Currie SL; Lin W; Tagliaferri MA; Zalevsky J; Sznol M; Hurwitz ME
J Clin Oncol; 2021 Sep; 39(26):2914-2925. PubMed ID: 34255535
[TBL] [Abstract][Full Text] [Related]
4. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Diab A; Tannir NM; Bentebibel SE; Hwu P; Papadimitrakopoulou V; Haymaker C; Kluger HM; Gettinger SN; Sznol M; Tykodi SS; Curti BD; Tagliaferri MA; Zalevsky J; Hannah AL; Hoch U; Aung S; Fanton C; Rizwan A; Iacucci E; Liao Y; Bernatchez C; Hurwitz ME; Cho DC
Cancer Discov; 2020 Aug; 10(8):1158-1173. PubMed ID: 32439653
[TBL] [Abstract][Full Text] [Related]
5. Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.
Khushalani NI; Diab A; Ascierto PA; Larkin J; Sandhu S; Sznol M; Koon HB; Jarkowski A; Zhou M; Statkevich P; Geese WJ; Long GV
Future Oncol; 2020 Oct; 16(28):2165-2175. PubMed ID: 32723187
[TBL] [Abstract][Full Text] [Related]
6. Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab.
Veatch JR; Singhi N; Jesernig B; Paulson KG; Zalevsky J; Iaccucci E; Tykodi SS; Riddell SR
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298619
[TBL] [Abstract][Full Text] [Related]
7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
8. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
[No Abstract] [Full Text] [Related]
9. Failure of adjuvant treatment for malignant melanoma - what next?
Žiaran M; Dvořák P; Hoffmann P; Kopecký J
Klin Onkol; 2021; 34(1):73-77. PubMed ID: 33657824
[TBL] [Abstract][Full Text] [Related]
10. Difficulties in differentiating between checkpoint inhibitor pneumonitis and lung metastasis in a patient with melanoma.
Safa H; Bhosale P; Weissferdt A; Oliva ICG
Immunotherapy; 2020 Apr; 12(5):293-298. PubMed ID: 32295435
[TBL] [Abstract][Full Text] [Related]
11. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
[TBL] [Abstract][Full Text] [Related]
12. Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma.
Baba T; Sakai F; Kato T; Kusumoto M; Kenmotsu H; Sugiura H; Tominaga J; Oikado K; Sata M; Endo M; Yanagawa N; Sasaki S; Iwasawa T; Saito Y; Fujiwara Y; Ohe Y; Yamazaki N; Sakamoto T; Koshiba T; Kuwano K
Future Oncol; 2019 Jun; 15(16):1911-1920. PubMed ID: 31020849
[No Abstract] [Full Text] [Related]
13. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
14. Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma.
Dimitriou F; Hauschild A; Mehnert JM; Long GV
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-22. PubMed ID: 35658500
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Ziogas DC; Theocharopoulos C; Koutouratsas T; Haanen J; Gogas H
Cancer Treat Rev; 2023 Feb; 113():102499. PubMed ID: 36542945
[TBL] [Abstract][Full Text] [Related]
16. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
Saito R; Sawada Y; Nakamura M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
[TBL] [Abstract][Full Text] [Related]
17. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
[TBL] [Abstract][Full Text] [Related]
18. Bluish-gray fingernail discoloration due to the use of nivolumab.
Ocampo MM; Lerner J; Dasanu CA
J Oncol Pharm Pract; 2021 Mar; 27(2):457-459. PubMed ID: 32517636
[TBL] [Abstract][Full Text] [Related]
19. Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution.
Kleef R; Nagy R; Baierl A; Bacher V; Bojar H; McKee DL; Moss R; Thoennissen NH; Szász M; Bakacs T
Cancer Immunol Immunother; 2021 May; 70(5):1393-1403. PubMed ID: 33151369
[TBL] [Abstract][Full Text] [Related]
20. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
